Cover Image
市場調查報告書

法布瑞氏症 - 機會分析及至2024年的預測

OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024

出版商 GlobalData 商品編碼 344234
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
法布瑞氏症 - 機會分析及至2024年的預測 OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024
出版日期: 2015年08月01日 內容資訊: 英文 133 Pages
簡介

全球法布瑞氏症市場2014年的銷售額在7大市場中成為6億8,200萬美元。美國有最大佔有率,達2億9,500萬美元。預計到2024年終的10年以年複合成長率6.3%持續擴大,擴大到12億5,000萬美元。

本報告提供法布瑞氏症的流行病學、病因、症狀、診斷、治療指南等概要,以及治療藥市場收益、至2024年的10年預測、市場上未滿足需求、開發平台趨勢等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
  • 症狀

第4章 流行病學

  • 背景
  • 風險因素和共生病症/前兆
  • 全球的趨勢
  • 預測方法
  • 流行病學的預測
  • 考察

第5章 目前治療方法

  • 概要
  • 產品簡介

第6章 未滿足需求的評估與機會分析

  • 概要
  • 早期診斷
  • 功效改善的治療方法
  • 低成本的治療方法
  • 改善適合性的家庭注射法的普及

第7章 研究開發策略

  • 概要
  • 臨床實驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發的潛力藥物
  • 創新的早期方法
  • 生技仿製藥

第9章 開發平台評估分析

  • 開發平台藥物的臨床基準
  • 開發平台藥物的商業性基準
  • 競爭評估
  • 10年預測
    • 美國
    • 歐洲5國
    • 日本
    • 促進要素與阻礙

第10章 附錄

圖表

目錄
Product Code: GDHC039POA

GlobalData estimates the 2014 sales for the Fabry disease market at approximately $682m across the 7MM. The US contributed the majority of these sales, generating an estimated $295m. By the end of the forecast period in 2024, Fabry disease sales are expected to grow to $1.25 billion at a Compound Annual Growth Rate (CAGR) of 6.3% over the 10-year period. The majority of sales in the 7MM in 2024 will come from the US, which will represent 44.2% of the market. GlobalData expects an increase in the number of newly diagnosed cases of Fabry disease, and consequently in the number of treatable Fabry patients, as a result of increasing awareness of Fabry disease among physicians. ERT is now well established in the treatment of Fabry disease; however, there still remains concern about its efficacy, tissue penetrance, and intravenous administration. As a result, alternative approaches are being investigated to advance new treatments for Fabry disease, which focus on three main areas of research: chaperone therapies, substrate reduction therapies (SRTs), and combinations of their use with ERT.

Highlights

Key Questions Answered

  • At present, patient registries demonstrate a long delay between onset of initial symptoms and a diagnosis, which can span between 10 to 20 years. This is due the condition being very rare, the lack of awareness of the disease among physicians, and the diverse range of symptoms that a patient may have when initially presenting with the disease. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs in this market?
  • Since the approval of Fabrazyme and Replagal in the EU in 2001, no other drugs have been approved for the treatment of Fabry disease. Will the pipeline drugs in development change the treatment landscape for Fabry disease and attain high sales revenues during 2014-2024?
  • Key opinion leaders interviewed by GlobalData believe the biggest opportunity lies with combination therapies, to improve drug delivery and increase drugs' efficacy,. How will these changes impact the growth of the future market?

Key Findings

  • One of the main drivers for the Fabry disease market growth will be an increase in the number of newly diagnosed cases of Fabry disease, and consequently in the number of treatable Fabry patients, as a result of increasing awareness of Fabry disease among physicians.
  • The first pharmacological chaperone for the treatment of Fabry disease, Amicus Therapeutics' migalastat, will launch in the US and 5EU (France, Germany, Italy, Spain, and UK) in 2017, followed by its launch in Japan in 2020. Migalastat patient share is not only expected to be captured from existing patients receiving enzyme replacement therapy (ERT), but also treatment-naive patients who have not previously been considered suitable for ERT.
  • There is a lack of suitable treatments available for young children with Fabry disease. ERT requires intravenous infusions every two weeks; hence, until orally available treatment options become available, such as Amicus' migalastat, it is expected that expansion of the Fabry disease market to include younger children will not occur.

Scope

  • Overview of Fabry disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized Fabry disease therapeutics market revenue, annual cost of therapy and treatment usage pattern data from from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Fabry disease therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global Fabry disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the Fabry disease therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Fabry disease therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM Fabry disease therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities/Manifestations
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases
  • 4.5. Epidemiological Forecast for Fabry Disease (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of Fabry Disease
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of Fabry Disease
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of Fabry Disease
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles
    • 5.2.1. Fabrazyme (Agalsidase Beta)
    • 5.2.2. Replagal (Agalsidase Alfa)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Earlier Fabry Disease Diagnosis
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Fabry Disease Treatments with Improved Efficacy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Fabry Treatments
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Widespread Availability of Home-Based Infusion to Improve Compliance
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Chaperone Therapies and Their Drug Combinations
    • 7.1.2. Substrate Reduction Therapies
  • 7.2. Clinical Trial Design
    • 7.2.1. Efficacy Endpoints
    • 7.2.2. Clinical Trial Treatment Periods
    • 7.2.3. Challenges in Fabry Disease Clinical Trials

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Migalastat
  • 8.3. Innovative Early-Stage Approaches
  • 8.4. Biosimilars

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line 10-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan
    • 9.4.4. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecast Methodology
    • 10.4.1. Percent Diagnosed Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Therapy Area Director
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Director of Therapy Analysis and Epidemiology
    • 10.6.5. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Pathophysiological Findings in Fabry Disease Tissue Specimens
  • Table 2: Typical Signs of Fabry Disease According to Patient Age
  • Table 3: 7MM, Sources of Fabry Disease Diagnosed Prevalence Data
  • Table 4: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, Selected Years 2014-2024
  • Table 5: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N (Row %), 2014
  • Table 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N (Row %), 2014
  • Table 7: Key Marketed Products for Fabry Disease, 7MM
  • Table 8: Guidelines for the Initiation of ERT in Fabry Disease Patients
  • Table 9: Product Profile - Fabrazyme
  • Table 10: Efficacy of Fabrazyme at Reducing GL-3 in the Capillary Endothelium of the Tissues
  • Table 11: Efficacy of Fabrazyme at Reducing Clinical Events
  • Table 12: Adverse Reactions Occurring in the 20-week Phase III Fabrazyme Study
  • Table 13: Summary of Adverse Reactions in the Phase IV Post-marketing Fabrazyme Study
  • Table 14: Fabrazyme SWOT Analysis, 2015
  • Table 15: Product Profile - Replagal
  • Table 16: Efficacy of Replagal at Reducing Overall Neuropathic Pain
  • Table 17: Replagal SWOT Analysis, 2015
  • Table 18: Unmet Need in Fabry Disease
  • Table 19: Late-Stage Pipeline Products for Fabry Disease, 7MM
  • Table 20: Product Profile - Migalastat
  • Table 21: Efficacy of Fabrazyme at Reducing GL-3 and Plasma Lyso-GL-3 in the Capillary Endothelium of the Tissues
  • Table 22: Summary of Migalastat Safety in Fabry Patients (Study 012)
  • Table 23: Migalastat SWOT Analysis, 2015
  • Table 24: Early-Stage Pipeline Products for Fabry Disease, 7MM
  • Table 25: Pipeline Agalsidase Biosimilars for Fabry Disease, 7MM
  • Table 26: Clinical Benchmark of Key Pipeline Drugs - Fabry Disease Treatments
  • Table 27: Commercial Benchmark of Key Pipeline Drugs - Fabry Disease Treatments
  • Table 28: Top-Line Sales Forecasts ($m) for the Fabry Disease Market in the 7MM, 2014-2024
  • Table 29: Key Events Impacting Sales in the Fabry Disease Market, 2014-2024
  • Table 30: Fabry Disease Market - Drivers and Barriers, 2014-2024
  • Table 31: Launch Dates in the Fabry disease Market, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N, 2014
  • Figure 4: Competitive assessment of Late Stage Pipeline Agents for Fabry Disease, 2014-2024
  • Figure 5: Sales for the Fabry Disease Market in the 7MM, 2014-2024
Back to Top